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Efficacy and safety of Glycebal (PDM011011) 
capsules as adjuvant therapy in subjects 
with type 2 diabetes mellitus: an open  
label, randomized, active controlled,  
phase II trial
ABSTRACT
Background. Momordica charantia is a medicinal plant 
used traditionally for treatment of various diseases 
including diabetes.
Objective. To evaluate the efficacy and safety of 
PDM011011 capsules (1.2 g/day) as an adjuvant thera­
py in subjects with type 2 diabetes mellitus (T2DM).
Methods. Each PDM011011 capsule contained 400 mg 
dry fruit juice powder of Momordica charantia. Ninety 
three T2DM patients receiving at least one oral hy­
poglycemic treatment were screened. The eligible 
85 subjects were randomized into 3:1 ratio in drug 
treatment (PDM011011 capsules) and placebo arm. 
Sixty­four patients received three 400 mg PDM011011 
capsules (1.2 g/day) while 21 patients received three 
placebo capsules per day for 90 days respectively. The 
primary efficacy endpoints were mean change in FPG, 
PPG level and HbA1c% from baseline to day 30, 60 and 
90 after interventions. 
Results. PDM011011­capsule (1.2 g/day) showed sig­
nificant reduction in FPG level by 14.59% after 90 days 
treatment, while patients receiving placebo capsules 
exhibited a marginal increase of 2.12%. The reduction 
in FPG level was statistically significant (p = 0.013) as 
compared with the placebo group. It also reduced PPG 
level by 22.21% as compared to the 3.71% reduction 
(p = 0.002) in placebo group. The encouraging reduc­
tion in HbA1c% in the drug group was 0.78 as compared 
to the placebo group with only 0.20 (p = 0.066). 
PDM011011 capsule showed no adverse events, seri­
ous adverse events and death in the study population.
Conclusion. PDM011011­capsule (1.2 g/day) showed 
good efficacy and safety; and it can be prescribed as 
an adjuvant therapy in subjects with T2DM. (Clin Diabet 
2016; 5, 3: 88–94)
Key words: type 2 diabetes mellitus, Momordica 
charantia, Glycebal, PDM011011 capsule, 
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Introduction
Diabetes mellitus (DM) is a progressive metabolic 
disorder characterized by increased blood glucose level 
for a long duration, insulin deficiency and insulin resist-
ance with disturbances of carbohydrate, fat and protein 
metabolism [1]. The long term hyperglycemia is associated 
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with macro and microvascular complications (dysfunction 
or failure of vital organs including eyes, heart, kidney, 
nerves and blood vessels) [2]. As per annual report of the 
international diabetes federation, 387 million people have 
DM and it will reach to 592 million by 2035 [3]. DM is 
predicted to affect 79.4 million people in India by 2030 
and the prevalence is increasing in rural population [4].
Type 2 DM (T2DM) predominantly occurs between 
age 45–64 and its development is based on various fac-
tors, including genetics, physical inactivity, sedentary 
lifestyle, obesity, smoking and substantial consumption 
of alcohol [5]. Pathophysiological conditions in T2DM 
are due to impaired insulin secretion by pancreatic b 
cells and insulin resistance or both. The reduction in 
insulin secretion is established gradually and comprises 
glucose and lipid toxicity [6].
In available treatment options, oral hypoglycemic 
agents and insulin supplement is backbone for man-
agement of DM. However, these are associated with 
side effects and fail to alter the progress of complica-
tions [7]. The most common side effects observed are 
hypoglycemia, increased body weight (Sulfonylureas, 
Meglitinides), peripheral edema, impaired liver function 
(Thiazolidinediones) [8] and gastrointestinal disorders 
(Dipeptidyl Peptidase-4 Inhibitors) [9]. Thiazolidine-
dione class is also allied with adverse effects mainly 
high risk of heart attack and bladder cancer [10, 11].
Herbal medicines are now in great demand for 
the treatment of DM as they are efficacious, produce 
relatively less or no side effects and are of relatively low 
cost compared with insulin and other oral hypoglycemic 
drugs [12, 13].
Momordica charantia (family Cucurbitaceae), bitter 
melon or bitter gourd is a medicinal plant used tradition-
ally for treatment of various diseases and known for vari-
ous pharmacological activities [14]. Studies conducted in 
streptozotocin induced diabetic rats and mice with Bitter 
melon have shown significant reduction of blood glucose 
levels [15]. Khanna et al. isolated polypeptide-p, from 
M. charantia which has shown effective hypoglycemic 
activity [16]. In many clinical studies M. charantia has 
shown beneficial effects in diabetic subjects [17, 18]. 
M. charantia is identified to contain several compounds 
such as mormordin, carotenoids, flavonoids, vitamin C, 
and polyphenols. The important compounds that have 
isolated from M. charantia and known as hypoglyce-
mic agents include charantin (a steroid glycoside), and 
polypeptide-p or plant insulin [19].
Existing marketed formulations containing bitter 
melon juice powder prepared by traditional methods 
may have risk of degradation of biomolecules before 
use. We developed a patented, novel method for the 
preparation of M. charantia juice powder which assures 
the stability of heat sensitive biomolecules. The present 
study was performed to evaluate the efficacy and 
safety of PDM011011 capsule as an adjuvant therapy 
in subjects with T2DM.
Materials and methods
Patients
Male or female patients of age > 30 and < 70 years 
with a clinical diagnosis of T2DM, stable for 6 months on 
any other anti-diabetic agents, prior to screening were 
recruited from 5 centers in India. Patients having fast-
ing plasma glucose of ≥ 110 mg/dl and £ 250 mg/dl; 
HbA1c > 7%, but < 10% at the time of randomization 
were included. Pregnant and lactating women, women 
of childbearing potential and men not agreeing to use 
adequate contraception methods during study, were 
excluded. Other exclusion criteria were subjects with 
type 1 DM, secondary DM, and clinically significant car-
diac disease, endocrine abnormalities other than stable 
thyroid disease or patients requiring insulin therapy and 
serum creatinine level more than 1.5 mg/dl.
The study was approved by an Institutional Review 
Boards and conducted in accordance with the ethical 
principles described in the Declaration of Helsinki. Writ-
ten informed consent was taken from all subjects prior 
to start of the study.
Plant material and drug preparation
Unripe green fruits of M. charantia, collected from 
the fields of Maharashtra, India were authenticated 
in Piramal Life Sciences Limited (PLSL), Mumbai India. 
The extraction process focuses on the juice expression 
of whole fruits with seeds, which is then processed 
and converted into a free-flowing natural green 
colored powder with a characteristic odor and taste. 
The processing of juice is a patented step, developed 
for the stabilization of heat sensitive bioactives. Each 
PDM011011-capsule contained 400 mg of dry stand-
ardized fruit juice powder with not less than 0.4 mg 
of Uridine as a chemical marker.
Study design
The present study was an open-label, randomized, 
active-controlled, phase II trial to evaluate efficacy and 
safety of PDM011011 capsules as an adjuvant therapy 
in subjects with T2DM. The study design consisted of 
total 5 visits; a screening visit, baseline visit, followed 
by three visits on day 30, 60 and 90, at which safety 
and efficacy assessments were performed. A total of 93 
patients were screened and 85 patients were enrolled 
at 5 sites in India. The eligible 85 subjects were rand-
omized into 3:1 ratio in drug treatment (PDM011011-
-capsule) and placebo arm. Sixty-four patients received 
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PDM011011 capsules (1.2 g/day) while 21 patients 
received placebo capsules for 90 days. Drug treatment 
arm received one PDM011011-capsule (400 mg) in the 
morning and two capsules in evening daily half-an-
hour before breakfast and dinner respectively. Similarly 
placebo capsules were received in the placebo arm.
Efficacy and safety assessment
The primary efficacy endpoints were mean change 
in fasting plasma glucose (FPG), postprandial blood 
sugar level (PPG) level and glycosylated hemoglobin 
(HbA1c) % from baseline to day 30, 60 and 90 after 
interventions. HbA1c% should be ≥ 7. The secondary 
efficacy endpoints were lipid profile and the general 
well-being of subjects during the treatment. Safety 
was monitored by assessing patient’s reported adverse 
events, physical examinations, vital signs, clinical labo-
ratory parameters as well as complete blood count.
Sample size and randomization
Determination of sample size was based on the 
outcome of oral treatment of the same drug and study’s 
assumption was done as follows: efficacy of the test 
drug (70%, 42 out of 60) and placebo (40%, 8 out of 
20) will have about 90% power to detect differences 
at alpha = 0.05. The randomization of all enrolled 
subjects was carried out by block randomization in 3:1 
ratio (drug:placebo).
Statistical analysis
Statistical analysis was performed by using SPSS 
V 10.0 package (Statistical Package for the Social Sci-
ences, Version 10.0). Data was given as Mean ± SD or 
Frequency (Percentage) as per the type of data. Stu-
dent’s paired‘t’ tests were applied to compare means of 
related (before–after) data. Student’s unpaired‘t’ tests 
were applied to compare means of unrelated data. Level 
of significance was taken as p = 0.05.
Results
Demographic and baseline characteristics
Out of 85 enrolled subjects, 79 completed the 
study, including 62 patients from PDM011011 group 
and 17 from the placebo group (Table 1). Six patients 
were lost to follow up; 2 from treatment group and 4 
from the placebo group and hence could not complete 
the study (Figure 1). The trial was performed in a real-
world clinical setting involving 5 Indian sites, started 
in June 26, 2012 and completed in October 17, 2012.
The demographic data evaluation was performed. 
The protocol population and the baseline characteristics 
were found comparable between the two groups (Table 2). 
The range of age in the study drug was 31–60 years 
and in the placebo group it was 31–55, thus similar 
age-wise distribution in both the groups was observed.
The baseline disease characteristics (Table 2) in 
terms of FPG, PPG level and HbA1c% were evaluated. 
The mean baseline FPG level in PDM 011011-group 
was 150.02 ± 35.2 mg/dl while in the placebo group it 
was 148.76 ± 34.8 mg/dl. The mean baseline PPG level 
was 202.40 ± 56.7 mg/dl in the treatment group and 
190.24 ± 54.3 mg/dl in the placebo group. The mean 
baseline HbA1c% level in the treatment group was 7.87 
± 1.0 and in the placebo group 7.83 ± 1.1 respectively.
Efficacy analysis
Primary efficacy endpoint assessments consisted of 
three parameters — FPG level, PPG level and HbA1c% 
Table 1. Patient disposition in the study
Disposition Number (%) of patients Total 
N = 85Study drug (PDM 011011) 
N = 64
Placebo 
N = 21
Enrolled subjects 64 (75.29%) 21 (24.70%) 85 (100%)
Subjects dosed 64 (75.29%) 21 (24.70%) 85 (100%)
Completed 62 (78.48%) 17 (21.51%) 79 (92.94%)
Prematurely withdrawn from study 02 (3.12%) 04 (9.52%) 06 (4.70%)
Consent withdrawn 0 (0.00%) 0 (0.00%) 0 (0.00%)
Investigator decision 0 (0.00%) 0 (0.00%) 0 (0.00%)
Ineligibility/Not meeting incl. criteria 0 (0.00%) 0 (0.00%) 0 (0.00%)
AE 0 (0.00%) 0 (0.00%) 0 (0.00%)
Lost to follow-up 2 (3.12%) 4 (9.52%) 6 (19.04%)
SAE/Death 0 (0.00%) 0 (0.00%) 0 (0.00%)
Other 0 (0.00%) 0 (0.00%) 0 (0.00%)
N — number of patients; AE — adverse events; SAE — serious adverse events
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Figure 1. CONSORT Flow Diagram (Patient disposition)
Table 2. Patient demographics and baseline characteristics
Parameter PDM 011011 treatment group  
N = 62
Placebo group 
N = 17
Gender, n (%)
Male 39 (62.90%) 10 (58.82%)
Female 23 (37.09%) 07 (41.50%)
Age
Mean age ± SD 41.33 ± 7.59 41.31 ± 6.88
Age range 31–60 31–55
Mean baseline FPG level ± SD [mg/dl] 150.02 ± 35.2 148.76 ± 34.8
Mean baseline PPG level ± SD [mg/dl] 202.40± 56.7 190.24 ± 54.3
Mean baseline HbA1c% level ± SD 7.87 ± 1.0 7.83 ± 1.1
Past/Receiving medications
Glibenclamide 14 03
Gliclazide 02 01
Metformin 19 07
Gliclazide with metformin 16 05
Glimpride 05 00
Herbal 02 01
Unknown 05 02
FPG — fasting plasma glucose level; PPG — postprandial blood sugar level; HbA1c — glycosylated hemoglobin
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as depicted in Table 3. The study drug showed signifi-
cant reduction of FPG level by 14.59% after 90 days 
treatment, while placebo group exhibited a marginal 
increase of 2.12% (Table 4). This reduction was statis-
tically significant (p = 0.013) when compared with 
the placebo group. The study drug also reduced PPG 
level by 22.21% as compared to the 3.71% reduction 
(p = 0.002) in the placebo group. However, there was 
no significant reduction observed in HbA1c% in both 
drug and placebo treated groups. The reduction in 
HbA1c% in the drug group which was 0.78 as compared 
to the placebo group with only 0.20 (p = 0.066) was 
encouraging.
Secondary efficacy endpoint assessments contain 
the lipid profiling of serum cholesterol, HDL (high den-
sity lipoprotein), LDL (low density lipoprotein), VLDL 
(very low density lipoprotein) and triglycerides. There 
was a reduction in the mean change from baseline to 
day-90 observed in both treatment and placebo group 
(Table 5).
Table 3. Summary statistics of fasting, postprandial blood sugar level and HbA1c%
Variable Group Baseline Day 30 Day 60 Day 90
FPG [mg/dl] Drug 150.02 ± 35.2 142.5 ± 21.2 135.43 ± 24.8 128.12 ± 16.8
Placebo 148.76 ± 34.8 145.35 ± 21.0 146.35 ± 21.3 150.88 ± 22.8
PPG [mg/dl] Drug 202.4 ± 56.7 179.16 ± 22.6 170.01 ± 26.4 157.45 ± 17.9
Placebo 190.23 ± 54.2 182.23 ± 28.3 182.76 ± 32.1 183.17 ± 30.5
HbA1c% Drug 7.87 ± 1.0 – – 7.08 ± 0.9
Placebo 7.83 ± 1.1 – – 7.62 ± 0.9
Values expressed as mean ± SD; Drug — PDM011011 capsule; FPG — fasting plasma glucose level; PPG — postprandial blood sugar level; HbA1c — glyco-
sylated hemoglobin
Table 4. Percent change in primary efficacy parameters after treatment
Parameters FPG [mg/dl] PPG [mg/dl] HbA1c (%)
Drug Placebo Drug Placebo Drug Placebo
Baseline 150.02 148.76 202.40 190.24 7.87 7.83
Post treatment (90 days) 128.13 150.88 157.45 183.18 7.08 7.62
Plasma glucose decrease during treatment period 21.89 –2.12 44.95 7.06 – –
Plasma glucose decrease (%) 14.59 –1.42 22.21 3.71 0.78 0.20
p value *p = 0.013 **p = 0.002 p = 0.066
Data was evaluated using Student’s unpaired t test; *Significant values at p < 0.05 compared to the placebo; **Significant values at p < 0.01 compared to 
the placebo; Drug — PDM011011 capsule; FPG — fasting plasma glucose level; PPG — postprandial blood sugar level; HbA1c — glycosylated hemoglobin
Table 5. Lipid profiling of subjects after treatment
Variable Treatment Baseline Day 90
Serum cholesterol [mg/dl] PDM011011 Drug 152.69 ± 27.27 146.48 ± 28.74
Placebo 154.23 ± 30.11 152.35 ± 29.11
HDL cholesterol [mg/dl] PDM011011 Drug 48.56 ± 5.93 47.52 ± 9.28
Placebo 48.52 ± 5.83 48.06 ± 7.71
LDL cholesterol [mg/dl] PDM011011 Drug 81.82 ± 24.15 77.45 ± 26.10
Placebo 84.16 ± 25.22 81.99 ± 23.38
VLDL cholesterol [mg/dl] PDM011011 Drug 22.31 ± 4.20 21.51 ± 3.95
Placebo 21.54 ± 4.68 22.31 ± 4.64
Triglycerides [mg/dl] PDM011011 Drug 111.55 ± 20.98 107.56 ± 19.75
Placebo 107.71 ± 23.40 111.53 ± 23.18
Values expressed as mean ± SD; HDL — high density lipoprotein; LDL — low density lipoprotein; VLDL — very low density lipoprotein
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Safety analysis
Safety analysis was carried out in terms of incidence 
of adverse events, hematological parameters, vital signs 
and physical examination. Treatment of PDM011011-
-capsule was well tolerated throughout the study. 
During 90 days treatment with PDM011011-capsule no 
adverse events or serious adverse events as well as no 
death was recorded. There was no significant change 
in the hematological parameters, blood chemistry and 
vital signs seen.
Discussion
The treatment with PDM011011-capsule signifi-
cantly reduced FPG level and PPG level, which confirms 
good hypoglycemic activity of the treatment drug. 
Treatment with PDM011011 capsules (1.2 g/day) for 3 
months reduced the FPG level by 14.59%, while slight 
increase of 2.12% was observed in patients receiving 
placebo capsules. The reduction in FPG level was sta-
tistically significant (p = 0.013) as compared with the 
placebo group. Rahman et al. mentioned significant 
reduction of the FPG level after treatment of 2 g/day 
and 4 g/day bitter melon powder for 10 weeks in T2DM 
patients [20]. In another study, it was observed that 
a 2 g/day dose of bitter melon for 4-weeks in T2DM 
patients significantly reduced blood glucose level by 
26.7 ± 40.8 mg/dl however the effect was less as com-
pared to 1 g/day dose of metformin [21]. In our study, 
results reported with lower dose (1.2 g/day) are found 
similar to the results reported with higher doses (2 g/day 
and 4 g/day) in other studies [20, 21].
In this study, the PPG level was also reduced by 
22.21% as compared to the 3.71% reduction (p = 0.002) 
in placebo after 90 days treatment. John et al. reported 
non-significant reduction (p > 0.05) in PPG level after 
treatment with bitter melon tablets (total 6 g/day) for 
4 weeks in T2DM patients. The change in PPG was 
30 mg/dl observed from baseline to endpoint [22]. 
In our study the most significant change in PPG was 
44.95 mg/dl seen from baseline to day-90.
The measurement of HbA1c% is the hallmark for 
overall control of diabetes and preventing associated 
complications [23]. A decline of 1% HbA1c might avert 
about 30–35% microvascular and 14–16% macrovas-
cular complications [24]. Our study-results denote that, 
a reduction in HbA1c% from baseline to end point in 
patients receiving PDM011011 capsules is higher than 
the placebo treated group. At day-90 the difference 
between mean reductions in HbA1c% was not statistically 
significant. These results were found similar to the study 
reported by Dans et al. in which non-significant decline 
in HbA1c% levels was seen in T2DM patients treated with 
bitter melon extract [25]. Rahman et al. also reported 
non-significant reduction in HbA1c% in T2DM patients 
receiving bitter melon powder for 10 weeks [20].
In our previous study, we assessed the effect of 
PDM011011-capsule (400 mg) bid in T2DM patients 
(n = 20) for 90 days. The reduction of FPG and PPG 
levels were 18.65% and 22.03% respectively, and 
1.1% reduction in the level of HbA1c% were observed. 
The outcomes of this pilot-study were comparable 
with present study. In addition, approximately 5% 
reduction in the body weight was observed in obese 
diabetes patients (n = 6) with weight (80 Kg) receiving 
PDM011011 capsules. Overall, 2.2% weight reduction 
was observed in diabetes patients and 0.6% weight 
gain was seen in patients receiving metformin tablets. 
The weight reduction is also an added improvement 
of PDM011011 capsule.
In the present study, the treatment of PDM011011-
-capsule in T2DM patients showed a mean reduction 
in levels of serum cholesterol, LDL cholesterol, VLDL 
cholesterol and triglycerides from baseline to the end-
point. These findings are similar to the study outcomes 
reported by Rahman et al. where the groups treated 
with bitter melon powder exhibited favorable changes 
in the blood lipid levels but not reached statistical sig-
nificance excluding the 4 g/day group [20].
PDM011011 capsule (1.2 g/day) was well tolerated 
and found to be safe during this study. Hematologi-
cal parameters and vital signs were reported normal 
in both treatment and placebo group. In the overall 
response assessed at the end of the study, all subjects 
showed excellent response to PDM011011-treatment, 
80% (49 out of 62). The remarkable reduction in the 
fasting glucose level, postprandial blood glucose level 
and HbA1c% confirms the anti-diabetic potential of 
PDM011011-capsule. It can be prescribed with other 
anti-diabetic drugs as adjuvant therapy in T2DM pa-
tients. Although PDM011011-capsule showed good 
efficacy, longer duration of clinical study is necessary 
to confirm the long term safety of the drug.
Conclusion
Glycebal-PDM011011 capsule showed good effi-
cacy and safety; and it can be prescribed as an adjuvant 
therapy in subjects with type 2 diabetes mellitus.
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